Home
Magna Scientia Advanced Biology and Pharmacy
Peer-Reviewed • ISSN: 2582-8363 • Fast-Track Publishing • Impact Factor 8.6 • Low Publication Charges • Crossref DOI Linking

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

Research and review articles are invited for publication in September - October 2026 (Volume 19, Issue 1) Submit manuscript

Biofilm-Associated Immune Vulnerability in Streptococcus pneumoniae: Virulence-Factor Remodeling and Therapeutic Implications for Invasive Disease

Breadcrumb

  • Home
  • Biofilm-Associated Immune Vulnerability in Streptococcus pneumoniae: Virulence-Factor Remodeling and Therapeutic Implications for Invasive Disease

Reuben Opoku 1, * and Isaac Nana Kissi Darko 2

1 Indiana University, Bloomington, IN, USA.
2 Independent Researcher, Texas, USA.

Research Article
 
Magna Scientia Advanced Biology and Pharmacy, 2026, 18(02), 076–081
Article DOI: 10.30574/msabp.2026.18.2.0061
DOI url: https://doi.org/10.30574/msabp.2026.18.2.0061

Received on 23 June 2026; revised on 29 July 2026; accepted on 31 July 2026

Streptococcus pneumoniae biofilms contribute to persistent carriage, immune evasion, and progression to invasive disease. Recent studies indicate that the biofilm state alters the display and function of key surface-associated virulence factors, including PspA, PspC, and LytA, and may reduce susceptibility to complement-mediated clearance and phagocytosis. At the same time, biofilm-dispersed pneumococci appear to elicit stronger innate immune activation than planktonic cells, suggesting that transition out of biofilm may expose a biologically vulnerable state. This review synthesizes recent peer-reviewed evidence on pneumococcal biofilm-associated immune interactions, focusing on virulence-factor remodeling, host recognition, and implications for therapy. Literature supports a state-dependent model of pathogenesis in which biofilm growth promotes persistence, whereas dispersion may increase immune visibility. However, current studies are heterogeneous in model system, assay design, and outcome measures, limiting direct quantitative synthesis. Standardized biofilm phenotyping and clinically linked validation studies are needed to determine whether biofilm-targeted or state-aware interventions can improve outcomes in invasive pneumococcal disease.

Streptococcus pneumoniae; Biofilm; Immune Evasion; Complement; Phagocytosis; PspA; PspC

https://msabp.magnascientiapub.com/sites/default/files/fulltext_pdf/MSABP-2026-…

Preview Article PDF

Reuben Opoku and Isaac Nana Kissi Darko. Biofilm-Associated Immune Vulnerability in Streptococcus pneumoniae: Virulence-Factor Remodeling and Therapeutic Implications for Invasive Disease. Magna Scientia Advanced Biology and Pharmacy, 2025, 18(02), 076–081. Article DOI: https://doi.org/10.30574/msabp.2026.18.2.0061

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 Magna Scientia Advanced Biology and Pharmacy - All rights reserved

Developed & Designed by VS Infosolution